RetiredUnitedHealthcarePolicy CS081LA.L

Nerve grafting to restore erectile function during/after radical prostatectomy (Louisiana) — Retired April 1, 2026

This policy addresses the use of autologous or allogenic nerve grafts (e.g., sural nerve grafting) to restore erectile function during or after radical prostatectomy for prostate cancer and applies to UnitedHealthcare's Louisiana plan.

Policy Summary

PayerUnitedHealthcare

PolicyNerve grafting to restore erectile function during/after radical prostatectomy (Louisiana) — Retired April 1, 2026

Policy CodePolicy CS081LA.L

Change TypeRetired (Louisiana plan disenrolled)

Effective DateFeb 1, 2026

Next Review Date

Key ActionDo not submit prior authorization requests for autologous or allogenic nerve grafting for erectile function under this Louisiana policy; the procedure is considered not medically necessary.

SourceLink

POLICY UPDATE CHANGES

Policy retired and Louisiana plan membership disenrolled on Apr. 1, 2026.

Supporting sections (Description of Services, Clinical Evidence, FDA, References) were updated to reflect current information as of 02/01/2026.

Retired policy; Louisiana plan membership disenrolled on Apr. 1, 2026.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

Louisiana-onlystate applicability

Insufficient evidencecoverage rationale

55899, 64999

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Not Medically Necessary (primary)

Covered when ALL of the following are met:

Primary coverage statement: Autologous or allogenic nerve grafts to restore erectile function during or after radical prostatectomy are considered unproven and not medically necessary due to insufficient evidence of efficacy.

Policy applies to Louisiana plan membership.

Autologous (for example, sural) or allogenic nerve grafts performed with the intent to restore erectile function during or after radical prostatectomy are excluded from coverage under this policy because they are considered unproven and not medically necessary.

This policy was retired for UnitedHealthcare’s Louisiana plan; Louisiana plan membership was disenrolled effective Apr. 1, 2026 per the policy history.

Nerve grafting procedures — whether autologous or allogenic — intended to restore erectile function during or after radical prostatectomy are considered not medically necessary due to insufficient quality scientific evidence demonstrating improved erectile outcomes.

Coding Information

Applicable Codes (listed for reference)CPT

55899	Unlisted procedure, male genital system.
64999	Unlisted procedure, nervous system

Provider Actions & Billing Guidance

Prior Authorization

Provider Actions — Autologous/Allogenic Nerve Grafting

Autologous (e.g., sural) or allogenic nerve grafting to restore erectile function during or after radical prostatectomy is considered unproven and not medically necessary. Prior authorization is not supportive for these procedures for restoration of erectile function; verify applicable benefit, state, or federal coverage requirements before proceeding.

Prior authorization: Not supportive for autologous/allogenic nerve grafting to restore erectile function (e.g., CPT 55899, 64999 may be used as unlisted references).
Claims handling: Deny as not medically necessary when requested to restore erectile function after radical prostatectomy unless the applicable contract/regulation requires coverage.
Documentation: If submitted, include operative report, rationale, and evidence; listing a code here does not imply coverage or guarantee payment.
Coding references (for provider billing reference only): Unlisted procedure, male genital system (CPT 55899); Unlisted procedure, nervous system (CPT 64999).
Clinical guidance: NCCN notes nerve grafting does not appear effective for patients undergoing wide resection of neurovascular bundles; recovery relates to nerve preservation, age, and preoperative function.

Background

Erectile dysfunction is a common consequence of radical prostatectomy, particularly when cavernous nerves are resected. When oncologic considerations permit, a nerve-sparing prostatectomy approach is used to preserve erectile function. For patients who require resection of cavernous nerves, techniques such as autologous sural nerve grafting or allogenic grafts have been proposed to restore function, but the clinical evidence is limited. Available literature includes single-arm and non-randomized observational studies suggesting possible benefit, while a randomized trial was stopped early for lack of benefit at interim analysis, supporting the conclusion that current evidence is insufficient to establish efficacy.

Definitions

inv-15: Sural nerve grafting (SNG) — definition and procedural description

DefinitionHarvesting a segment of the sural nerve (a sensory nerve alongside the short saphenous vein in the lower leg) and grafting it to the proximal and distal ends of resected cavernous nerves during radical prostatectomy to attempt restoration of erectile function.

Donor siteSural nerve (expendable sensory nerve from the lower leg) — most commonly used donor nerve for this procedure.

Procedure descriptionA portion of the sural nerve is harvested from one leg and joined to the distal and proximal ends of the resected cavernous nerve; grafting may be performed on one or both cavernous nerves.

PurposeIntended to increase the likelihood of restoring spontaneous erectile function after resection of cavernous nerves during radical prostatectomy.

Coding examples (reference only)Unlisted procedure, male genital system — 55899; Unlisted procedure, nervous system — 64999.

Billing Rule

Provider Actions & Claims/Billing Guidance

Operational guidance for providers and billing staff: if nerve grafting procedures are submitted for restoration of erectile function after radical prostatectomy, process claims per the member's benefit contract; if no contrary benefit requirement exists, these services are not covered as they are unproven.

Provider action: Obtain and document pertinent operative reports and clinical rationale if submitting for review; anticipate denial when benefit terms align with this policy.
Billing rule: Use appropriate unlisted CPT codes (e.g., 55899, 64999) where applicable — inclusion of codes is for reference and does not imply coverage.
Denial risk: High for requests to perform nerve grafting to restore erectile function absent contractually mandated coverage or robust supporting evidence.

DefinitionUse of spider silk conduit material (major-ampullate-dragline from Nephila edulis) placed along the neurovascular bundle sites during robotic radical prostatectomy as a conduit to promote erectile nerve regeneration.

Procedure descriptionAfter prostate removal with unilateral or bilateral nerve-sparing, spider silk is laid out on the dissected neurovascular bundle sites to contact proximal and distal ends and act as a conduit for nerve regeneration; reported as intraoperative placement during robotic RP.

Reported outcomesIn a small case series (six patients) placement was uneventful, inflammatory markers peaked early then stabilized, and three patients reported erections sufficient for penetration at three months with continued improvement up to 18 months; authors call for prospective randomized trials.

Safety/feasibilityCase series reported simple intraoperative handling without major complications; one readmission (urinary tract infection) reported; no antibiotics required for silk contact-related inflammation during hospitalization.